2022 International Virtual Conference
on Human Retrovirology: HTLV 2022
8 - 11 May 2022
VIRTUAL

Day 1 of the conference will begin at the following times

  • Honolulu, HI, USA  – 19:00, Saturday, 7 May 2022
  • Phoenix, AZ, USA  – 22:00, Saturday, 7 May 2022
  • Baltimore, MD, USA  – 01:00, Sunday, 8 May 2022
  • Sao Paulo, Brazil  – 02:00, Sunday, 8 May 2022
  • London, UK  – 06:00, Sunday, 8 May 2022
  • Berlin, Germany  – 07:00, Sunday, 8 May 2022
  • Shanghai, China  – 13:00, Sunday, 8 May 2022
  • Tokyo, Japan  – 14:00, Sunday, 8 May 2022
  • Melbourne, Australia  – 15:00, Sunday, 8 May 2022
  • Auckland, New Zealand  – 17:00, Sunday, 8 May 2022

To view the program in your local time, you can use the time zone converter tool here.

Please note that the program times are not the same for each day of the conference. Please check the other days to confirm starting time. The below times are listed in Australian Eastern Standard Time (Melbourne).

The program is in draft and is subject to change.

15:00 – 16:30

Opening Ceremony

Chairs: Damian Purcell and Fabiola Martin

Welcome to Country

Committee Welcome and IRVA President IntroductionProfessor Damian Purcell and Dr Fabiola Martin

Australian Government Welcome – Hon Greg Hunt MP, Minister for Health and Aged Care

Women and HTLV – Invited speaker: Sandra do Valle, Brazil

20-year history of the Japanese HAM Patients Association – Invited speaker: Mr Shu Ishimoda, Smile Ribbon, Japan

My Story: Lack of HTLV-1 STI screening and referral pathways in Australia –  Invited speaker: Ms Joanna Curteis, Patient Representative, Australia

Keynote Address – HTLV Research Successes, set-backs and strategies – Professor Graham Taylor, Imperial College, London UK

16:30 – 16:45

Break

16:45 – 17:47

2. Viral-host Interactions for HTLV-1 Transmission

Chairs: Helene Dutarte & Andrea Thoma-Kress

Viral Transmission
Invited speaker: Louis Mansky, Institute for Molecular Viroligy, USA

#18 Role of tetraspanins in HTLV-1 biofilm formation
Coline Arone, Université de Montpellier, France

#33 The helicase-like transcription factor inhibits infectious replication of human T-cell leukemia virus type 1.
Aurélie Beauvois, University of Liège, Belgium

#91 Transient expression of HTLV-1 Tax induces epigenetic alterations and mimics early T-cell activation
Daisuke Kurita, Kumamoto University, Japan

#71 HTLV-1 Retrovirus is Not Detected by Dendritic Cells but Alters their Response to a Restimulation
Auriane Carcone, Centre International de Recherche en Infectiologie, France

Panel Discussion and Q&A (15mins)

17:47 – 18:30

Break

18:30 – 19:32

3. Unravelling the molecular events in pathogenesis of HTLV-1

19:32 – 19:45

Break

19:45 – 20:55

4. Who has HTLV-1 infection and where

Chairs: John Kaldor and Belinda Greenwood Smith

Global epidemiological aspects of HTLV-1 in the world with a focus on Africa, the largest HTLV-1 endemic area
Invited Speaker: Antoine Gessain, Pasteur France, France

#25 Prevalence and risk factors for human T-cell lymphotropic virus (HTLV) in blood donors in Brazil – a 10-year study (2007-2016).
Carolina Miranda, Universidade Federal De Minas Gerais, Brazil

#34 Prevalences Of HTLV, HIV And HBV In Patients Receiving Blood Transfusions In South Africa
Reynier Willemse, Sanbs, South Africa

#76 20 years of HTLV screening of blood donations in the UK
Ruth Wilkie, NHSBT, United Kingdom

#203 Retrospective study of Human T-cell Leukaemia Virus Type 1 & Adult T-cell Leukaemia/Lymphoma in Queensland, Australia.
Robert Gibb, Pathology Queensland, Australia

#61 Recent advances in HTLV-1 epidemiology.
Edward Murphy, UCSF and Vitalant Research Institute, United States

Panel Discussion and Q&A (15mins)

To view the program in your local time, you can use the time zone converter tool here.

Day 2 of the conference will begin at the following times

  • Honolulu, HI, USA  – 11:00, Sunday, 8 May 2022
  • Phoenix, AZ, USA  – 14:00, Sunday, 8 May 2022
  • Baltimore, MD, USA  – 17:00, Sunday, 8 May 2022
  • Sao Paulo, Brazil  – 18:00, Sunday, 8 May 2022
  • London, UK  – 22:00, Sunday, 8 May 2022
  • Berlin, Germany  – 23:00, Sunday, 8 May 2022
  • Shanghai, China  – 05:00, Monday, 9 May 2022
  • Tokyo, Japan  – 06:00, Monday, 9 May 2022
  • Melbourne, Australia  – 07:00, Monday, 9 May 2022
  • Auckland, New Zealand  – 09:00, Monday, 9 May 2022

Please note that the program times are not the same for each day of the conference. Please check the other days to confirm starting time.

The below times are listed in Australian Eastern Standard Time (Melbourne)

07:00 – 08:02

5. Animal models for HTLV

Chairs: Luc Willems and Patrick Green

#145 Bovine leukemia virus antisense transcription regulates viral replication, affects gene expression and directs host cell fate
Thomas Joris, Université de Liège, Belgium

#74 Single-cell NGS methods to track tumor precursor cells in HTLV-1 and BLV leukemia models
Jerome Wayet, Uliege, Belgium

#125 CD8+ cell depletion results in an increase in proviral loads in HTLV-1-infected cynomolgus macaques
Midori Nakamura-Hoshi, National Institute of Infectious Diseases, Japan

#72 Transient viral activation in HTLV-1-infected macaques treated with pomalidomide
Anna Gutowska, National Institutes Of Health, Vaccine Branch, United States

#24 The actin-bundling protein Fascin contributes to HTLV-1-induced lymphomagenesis in an ATLL xenograft mouse model
Andrea K. Thoma-Kress, Universitätsklinikum Erlangen, Virologisches Institut, Germany

#129 Combination antiretroviral therapy and MCL1 inhibition mitigate HTLV-1 infection in vivo
James Cooney, The Walter and Eliza Hall Institute, Australia

#75 Intragenic viral enhancer of HTLV-1 is dispensable for in vitro immortalization and in vivo persistence
Victoria Maksimova, The Ohio State University, United States

Panel Discussion and Q&A (25mins)

08:02 – 08:15

Break

08:15 – 09:17

6. How can testing improve clinical management?

Chairs: Philippa Hetzel and Junji Yamauchi

History of the HAM/TSP biomarker research
Invited Speaker: Yoshihisa Yamano, St. Marianna University School of Medicine, Japan

#126 Seroprevalence of neutralising antibodies in an HTLV-1c+ First Nations cohort from central Australia.
Samantha Gimley, The Peter Doherty Institute For Infection And Immunity, Australia

#153 Development of a pan-HTLV-1 Proviral Load Assay in Australia
Nick Vandegraaff, NRL/SVI, Australia

#83 Systemic cytokines and GlycA discriminate disease status and predict corticosteroid response in HTLV-1-associated neuroinflammation
Tatiane Assone, Fmusp, Brazil

#123 Flow cytometric assessment of T cell clonality for early detection of ATL: experience in the clinic
Aileen Rowan, Imperial College London, UK

Panel Discussion and Q&A (15mins)

09:17 – 09:45

Break

09:45 – 10:47

7. Clinical manifestations and biomarkers of disease during HTLV infection

Chairs: Yoshi Yamano and Mari Kannagi

Overall picture of genetic, epigenetic, and transcriptomic characteristics in ATL and HAM/TSP.
Invited Speaker: Makoto Yamagishi, The University of Tokyo, Tokyo, Japan

#136 Genome-wide association study of HAM/TSP susceptibility in Brazil reveals both immune and neural genetic links
Johan Van Weyenbergh, Ku Leuven, Belgium

#69 NGS quantification of viral clonal architecture identifies HTLV-1 asymptomatic carriers at high risk of progression to aggressive leukemia
Snehal Dilip Karpe, Laboratory of Viral Oncogenesis, Institut Jules Bordet, ULB & Unit of Animal Genomics, Belgium

#26 Role Of CTCF In Htlv-1 DNA Methylation, Gene Expression And Pathogenesis
Ancy Joseph, Washington University in Saint Louis, United States

#142 Analysis of neuroinflammatory biomarkers in HTLV-1-associated neurological disorders
Marzia Puccioni, Universidade Federal do Estado do Rio de Janeiro – UNIRIO, Brazil

Panel Discussion and Q&A (15mins)

10:47 – 11:00

Break

11:00 – 12:02

8. Key populations – Understanding and responding to HTLV in Vulnerable and First Nations Peoples

Chairs: Eduardo Gotuzzo and Ricardo Ishak

HTLV among vulnerable and indigenous communities in Brazil
Invited Speaker: Antonio Vallinoto, Universidade Federal do Pará, Brazil

HTLV-1 in Mahad/Iran: A Patient Perspective

#63 A qualitative study exploring perceptions to the human T cell leukaemia virus type 1 in Central Australia: Barriers to preventing transmission in a remote Aboriginal population
Fiona Fowler, Alice Salomon University of Applied Science, Australia

#133 Immune activation and dysfunction are defining characteristics of every HTLV-1c infection
Ashley Hirons, University Of Melbourne, Australia

#116 Determinants for the HTLV-1 maternal-to-child Transmission.
Gabriela Prates, Institute of Tropical Medicine, Brazil

Panel Discussion and Q&A (15mins)

12:02 – 12:15

Break

12:15 – 13:15

Sponsored Satellite Session – Cybernics Medical Innovation with Wearable Cyborg HAL

Chairs: Yoshi Yamano and Charles Bangham

Speaker: Yoshiyuki Sankai, President and CEO of CYBERDYNE Inc. Professor, Executive Research Director of Center for Cybernics Research, Director of F-MIRAI (R&D Center for Frontiers of MIRAI in Policy and Technology), University of Tsukuba, Japan

To view the program in your local time, you can use the time zone converter tool here.

Day 3 of the conference will begin at the following times

  • Honolulu, HI, USA  – 19:00, Monday, 9 May 2022
  • Phoenix, AZ, USA  – 22:00, Monday, 9 May 2022
  • Baltimore, MD, USA  – 01:00, Tuesday, 10 May 2022
  • Sao Paulo, Brazil  – 02:00, Tuesday, 10 May 2022
  • London, UK  – 06:00, Tuesday, 10 May 2022
  • Berlin, Germany  – 07:00, Tuesday, 10 May 2022
  • Shanghai, China  – 13:00, Tuesday, 10 May 2022
  • Tokyo, Japan  – 14:00, Tuesday, 10 May 2022
  • Melbourne, Australia  – 15:00, Tuesday, 10 May 2022
  • Auckland, New Zealand  – 17:00, Tuesday, 10 May 2022

Please note that the program times are not the same for each day of the conference. Please check the other days to confirm starting time.

The below times are listed in Australian Eastern Standard Time (Melbourne)

7:00 – 8:45

IRVA AGM

Welcome all existing and new IRVA members: Membership Secretary (FG) & President (FM)

Introductions to Board of Directors and Executive Committee members: Secretary (PJ)

President’s Report: President

Treasurer’s Report: Treasurer (AP)

Award Ceremony: Award Secretary (OH) & President

Closure: Secretary

15:00 – 16:02

9. HTLV-1 Community Perspective

Chairs: Fabiola Martin and Lloyd Einsendel

Invited Speaker Presentation
Achilea Bittencourt, Brazil

#113 HTLV Channel: Increasing awareness about HTLV
Carolina Rosadas, Imperial College London, United Kingdom

#156 The Epidemiology and clinical manifestations of the human T cell leukaemia virus Type 1C in remote Australian Aboriginal communities
Lloyd Einsiedel, Peter Doherty Institute, Australia

#49 Evidence of zoonotic and nosocomial transmission of htlv-1 in large survey in rural population of central Africa
Jil-Lea Ramassamy, Institute Pasteur, France

#97 The UK’s HTLV National Register: a unique cohort to inform disease progression
Katy Davison, Public Health England, United Kingdom

Panel Discussion and Q&A (15mins)

16:02 – 16:15

Break

16:15 – 17:17

10. Cutting-edge genomics approaches to improve our understanding of HTLV-1 associated disease

Chairs: Anne Van den Broeke and Franck Mortreux

Advanced sequencing technologies reveal new insights into oncogenic mechanism induced by HTLV-1
Invited Speaker: Dr Yorifumi Satou

#52 Chronological genome and single-cell epigenome/transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma
Makoto Yamagashi, The University of Tokyo, Japan

#105 Dominant clones in high-risk HTLV-1 carriers have a genetic and transcriptomic profile closely resembling ATL clones
Sonia Wolf, Imperial College, United Kingdom

#102 Changes in 3D chromatin architecture upon NF-κB activation by TAX involve transcriptional and alternative splicing regulations
Paul Marie, Laboratory of Biology and Modelling of the Cell, France

#43 The dynamics and consequences of HTLV-1 Tax expression in naturally infected T-cell clones
Saumya Ramanayake, Imperial College London, United Kingdom

Panel Discussion and Q&A (15mins)

17:17 – 17:45

Break

17:45 – 19:02

11. Prevention Strategies

Chairs: Graham Taylor and Beatrice Macchi

Public health response to HTLV
Invited Speaker: Peter Figueroa, Jamaica

#54 Cellular proteins of the vesicular trafficking pathway regulate HTLV-1 retention in viral biofilm and infectivity of chronically infected cells
Helene Dutartre, Inserm. Ciri – Lyon, France

#37 Cryo-EM structures of the deltaretroviral intasome in complex with the host factor Protein Phosphatase 2A subunit B56γ and HIV integrase inhibitors.
Goedele N. Maertens, Imperial College London, United Kingdom

#109 HTLV seroprevalence among HIV PrEP users in England
Daniel Bradshaw, Uk Health Security Agency, United Kingdom

#85 Strengths, weaknesses, opportunities & threats for the implementation of public health policies on htlv-1 in Brazil: a swot analysis
Ricardo Ishak, Universidade Federal Do Para, Brazil

HTLV-1: Applying a global public health approach – Challenges and opportunities
Invited Speaker: Meg Doherty, World Health Organisation, Switzerland

Panel Discussion and Q&A (15mins)

19:02 – 19:15

Break

19:15 – 20:25

12. Clinical Trials (phase 1-IV)

Chairs: Lucy Cook and Masao Matsuoka

Novel approaches to future management of ATLL
Invited Speaker: Makoto Yoshimitsu, Kagoshima University Hospital, Japan

#39 First-in-human experience with hypomethylating agents and Venetoclax in Relapsed/Refractory North American Adult T-Cell Leukemia and Lymphoma patients (NA ATLL)
R. Alejandro Sica, Montefiore Einstein Center For Cancer Care, United States

#148 A Phase II Trial of Belinostat as Consolidation Therapy with Zidovudine for Adult T-Cell Leukemia-Lymphoma (ATLL): Interim Results
Juan Carlos Ramos, University of Miami- Sylvester Comprehensive Cancer Center, United States

#121 Efficacy and safety of brentuximab vedotin in adult T-cell leukemia/lymphoma
Nobuaki Nakano, Imamura General Hospital, Japan

#168 Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukemia-lymphoma (ATL)
Hiro Tatetsu, Kumamoto University Hospital, Japan

#64 A randomized controlled trial on corticosteroid therapy for HTLV-1-associated myelopathy/tropical spastic paraparesis in Japan (HAMLET-P trial)
Junji Yamauchi, St. Marianna University, Japan

Panel Discussion and Q&A (15mins)

To view the program in your local time, you can use the time zone converter tool here.

Day 4 of the conference will begin at the following times

  • Honolulu, HI, USA  – 11:00, Tuesday, 10 May 2022
  • Phoenix, AZ, USA  – 14:00, Tuesday, 10 May 2022
  • Baltimore, MD, USA  – 17:00, Tuesday, 10 May 2022
  • Sao Paulo, Brazil  – 18:00, Tuesday, 10 May 2022
  • London, UK  – 22:00, Tuesday, 10 May 2022
  • Berlin, Germany  – 23:00, Tuesday, 10 May 2022
  • Shanghai, China  – 05:00, Wednesday, 11 May 2022
  • Tokyo, Japan  – 06:00, Wednesday, 11 May 2022
  • Melbourne, Australia  – 07:00, Wednesday, 11 May 2022
  • Auckland, New Zealand  – 09:00, Wednesday, 11 May 2022

The below times are listed in Australian Eastern Standard Time (Melbourne)

07:00 – 08:02

13. Non-Pharmacological/Behavioural Science

Chairs: Mrs Adine Adonis and Dr Mirna Biglione

Physiotherapy for Individuals with HAM/TSP
Invited Speaker: Katia Sá, Escola Bahiana de Medicina e Saúde Pública, Brazil

#38 Neurofunctional physical therapy protocol in patients with associated myelopathy to HTLV-1 (HAM).
Denise Goncalves, Ufmg, Brazil

#2 Prevalence and factors associated with depression and anxiety in people living with HTLV-1: A systematic review with meta-analysis and meta-regression
Lucca Souza, Federal University of Bahia, Brazil

#90 Multinational cross-sectional study on provision of HTLV care for blood donors with HTLV reactive serology
Fabiola Martin, University Of Queensland, Australia

#128 Defining research priorities for people living with HTLV-1 through patient/public involvement and engagement (PPIE) workshops
Adine Adonis, Imperial College Healthcare NHS Trust, United Kingdom

Panel Discussion and Q&A (15mins)

08:02 – 08:15

Break

08:15 – 09:17

14. Responding to co-infections

Chairs: Marzia Puccioni & Carolina Rosadas

Overview of HTLV-1 co-infections
Invited Speaker: Fernanda Grassi, Fiocruz, Brazil

#35 Human T-Lymphotropic virus type 1 and Human Immunodeficiency Virus co-infection in rural Gabon, Central Africa
Augustin Ghislain MOUINGA ONDEME, International Centre for Medical Research, Gabon

#202 COVID infection in patients with Human T-cell Leukemia Virus Type 1 (HTLV-1) infection, in Peru. Cases report
Eduardo Gotuzzo, Universidad Peruana Cayetano Heredia

#8 COVID-19 in individuals with HTLV-1 infection in Rio de Janeiro
Stephanie Monnerat, Universidade Federal Do Estado Do Rio De Janeiro, Brazil

#107 SARS-COV-2 Vaccination in people living with HTLV: vaccine hesitancy and antibody response
Divya Dhasmana, National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, London, United Kingdom

Panel Discussion and Q&A (15mins)

09:17 – 09:45

Break

09:45 – 10:47

15. Prospects for HTLV-1 preventive and therapeutic vaccines

Chairs: Genoveffa Franchini and Damian Purcell

A safe attenuated vaccine that protects from bovine leukemia virus infection in herds
Luc Willems, FNRS-ULiege, Belgium

#155 Preclinical evaluation of a subunit vaccine platform for HTLV-1
Keith Chappell, The University Of Queensland, Australia

#58 Potential anti-ATL therapeutic vaccine using short-term cultured autologous peripheral blood mononuclear cells: preclinical evidence in vitro and in vivo
Mari Kannagi, Department of Microbiology, Kansai Medical University, Japan

#46 In vivo and in vitro immunogenicity of novel MHC class I presented epitopes for a therapeutic peptide-based vaccine against HTLV-1.
Rashida Ginwala, Department of Medicine, Imperial College, United Kingdom

Panel Discussion
Luc Willems, Tetsuro Matano, Charles Bangham, Pooja Jain, Keith Chappell, Mari Kannagi, Rashida Ginwala, and Joanna Curteis

10:47 – 11:00

Break

11:00 – 12:30

16. Closing Plenary

Chairs: Fabiola Martin and Damian Purcell

Keynote Address – HIV vaccine efforts relevant the development of preventive HTLV-1 vaccines 
Dr Genoveffa Franchini, National Institutes of Health, Vaccine Branch, USA

Patient Presentation – Invited Speaker: Joanna Curteis

Poster Awards

Closing Remarks and future announcements

Posters are listed by theme and alphabetical order of author.

Poster listing is subject to change.

Please click on the poster name to view the abstract.

PO001 – High-resolution structural analysis of capsid-capsid interactions reveals novel insights into HTLV-1 particle morphology

William Arndt, University Of Minnesota – Twin Citites, United States


PO003 – Enriched cell pathways associated with dysregulated miRNAs expression by HTLV-2 infection

Andrea Corsi, University Of Verona, Italy


PO005 – HTLV-1 Subtype C chronically infected cell line clones for the in-vitro study of viral transmission and pathogenesis.

Peter Ellenberg, University of Melbourne, Australia


PO006 – Immunophenotypic characterization in CSF of patients with virus-associated neuroinflammatory diseases

Yoshimi Enose-Akahata, Viral Immunology Section, NINDS, NIH, United States


PO007 – CSF antibody profiling of patients with HTLV-1 associated myelopathy/ tropical spastic paraparesis using VirScan

Yoshimi Enose-Akahata, Viral Immunology Section, NINDS, NIH, United States


PO008 – EPZ015666, a PRMT5 inhibitor, selectively targets HTLV-1-infected T-cell lines in vitro and in vivo

Kyle Ernzen, The Ohio State University, United States


PO009 – HTLV-1 proviral load in vaginal fluid correlates directly with proviral load in peripheral blood mononuclear cells of infected women

Alisson Firmino, Bahiana School Of Medicine And Public Health, Brazil


PO010 – Immunogenic synthetic peptides: candidates for HTLV test of point of care development

Victor Folgosi, Laboratório De Dermatologia e Imunodeficiências, Instituto De Medicina Tropical De São Paulo / USP, Brazil


PO011 – Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of Adult T cell Leukemia

Greta Forlani, University Of Insubria, Italy


PO012 – Bio-id proximity mapping identifies cep63 as a centrosomal target of htlv-1 tax oncoprotein

Janelle Gauthier, CIRI, Centre International de Recherche en Infectiologie, France


PO013 – Cerebrospinal fluid chitotriosidase-1 as a candidate biomarker for the progression of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)

Yago Gomes, Ioc/fiocruz, Brazil


PO014 – Transcriptomic analysis of HTLV-1 infection in T-cells reveals novel insights into virus-host cell interactions important for virus assembly and infectious spread

Heather Hanson, University Of Minnesota, United States


PO015 – Induction of the tumor marker Fascin by HTLV Tax-1 and Tax-2 is linked to alternative NF-κB signaling

Stefanie Heym, Institute Of Clinical And Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany


PO004 – Arsenic/Interferon α-induced selective eradication of leukemia-initiating activity in adult T cell leukemia: Loss of interleukin-10 and activation of innate immune microenvironment response

Rita Hleihel, American University Of Beirut, Lebanon


PO017 – Simplified detection method for the clonality of Bovine leukemia virus-infected cells and early diagnosis of Enzootic Bovine Leukosis

Md Belal Hossain, Kumamoto University, Japan


PO018 – Improved cytotoxicity of antiretroviral drug Lopinavir in combination with flavonoid Apigenin in a manner similar to the antagonist of Aryl-hydrocarbon receptor

Dominic Sales, Drexel University, United States


PO019 – Role of cell surface and soluble/extra vesicular immune checkpoint molecules in determining the quality of anti-HTLV-1 CD8 T-cell response.

Julie Joseph, Drexel University, United States


PO020 – 3’LTR occupancy by MEF-2C/Menin drives Adult T-cell Leukemia via HBZ

Pooja Jain, Drexel University, United States


PO022 – Extracellular vesicles (EVs) from HTLV-1 infected cells possess subpopulation-specific malignant transformation effects upon uninfected cells.

Zach Cuba, George Mason University, United States


PO024 – Effect of Extracellular Vesicles (EVs) from HTLV-1 on Cell Proliferation via “Autocrine” Feedback Loop

Sarah Al Sharif, George Mason University, United States


PO025 – Wiskott-Aldrich syndrome protein (WASP) is a novel interaction partner of HTLV-1 p8 and may contribute to p8 transfer between cells

Laura M. Kemeter, Institute Of Clinical And Molecular Virology, Friedrich-alexander Universität Erlangen-nürnberg, Germany


PO026 – Temporal host transcription during spontaneous HTLV-1 proviral reactivation

Helen Kiik, Imperial College London, United Kingdom


PO027 – Elucidating the formation of a multimeric protein complex with HTLV-1 Tax and its impact on viral replication

Stephan Kohrt, Institute Of Clinical And Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany


PO028 – HBZ-related dysregulation of circular RNAs (circRNA) expression in ATLL

Julien Ladet, Laboratory of Biology and Modelling of the Cell, France


PO029 – ERK-signaling regulates Human T Cell Leukemia Virus Type 1 RNA stability and gene expression in latently-infected CD4 T cells

hsin-ching lin, Rutgers University, United States


PO030 – Investigating the Role of Base-Triples in the HTLV-1 pro-pol Frameshift Site Pseudoknot

Madison Maille, Loyola Marymount University, United States


PO032 – Neurofilament Light in HTLV-1 Associated Myelopathy: Evaluation of Clinical, Radiological and Immuno-virological correlations

Yair Mina, NINDS, NIH, United States


PO033 – Interactome and epigenetic functions of HTLV-1 Tax

Jun Mizuike, The University of Tokyo, Japan


PO034 – The retroviral transporter Rex hijacks the RNA helicase UPF1 in a CRM1 dependent manner.

Vincent Mocquet, ENS De Lyon, France


PO035 – KDR/VEGFR2 interacts with HTLV-1 Tax and prevents its autophagic degradation

Suchitra Mohanty, Penn State University College Of Medicine, United States


PO037 – Role of Monocytes, CTL and NK cells in primary HTLV-1 infection

Ramona Moles, National Institutes Of Health, Vaccine Branch, United States


PO038 – Identification of chloroquine/hydroxychloroquine as candidate therapeutic agents for adult T-cell leukemia/lymphoma

Shingo Nakahata, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Japan


PO039 – Whole genome sequence analysis of human T-cell leukemia virus type 1 in Peru

Shingo Nakahata, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Japan


PO040 – Analysis in the mechanism of co-operative and mutual regulation among viral proteins in HTLV-1 infection

Nakano Nakano, Grad. Sch. Frontier Sci., The University of Tokyo, Japan


PO041 – Valemetostat, an EZH1/2 inhibitor, suppresses HTLV-1 infection in a humanized mouse model

Tokifumi Odaka, Kansai Medical University, Japan


PO043 – Analysis of EV Signatures from HAM/TSP Patient CSF

Michelle Pleet, NIH/NINDS, United States


PO044 – Modeling tumor-bone interactions in ATL with HTLV-1-infected peripheral blood cell lines

Nitin Pokhrel, Washington University in St Louis, United States


PO045 – Role of protein kinase cβ in adult t-cell leukemia lymphoma

Lee Ratner, Washington University, United States


PO046 – Viral clonal landscape and tumor progression: lessons from tumor-resistant sheep in the BLV leukemia model

Anne-sophie Reuter, Uliege, Belgium


PO047 – Construction and Characterization of two Chimeric HTLV-1AC infectious Molecular Clones

Sarkis Sarkis, National Institutes Of Health, Vaccine Branch, United States


PO048 – Evaluation of quantification method of HTLV-1 proviral load in white blood cells using whole blood

Tomoo Sato, St. Marianna University School of Medicine, Japan


PO049 – Panobinostat and Romidepsin enhance Tax transcription but only moderately Tax protein in Tax-expressing, HTLV-1-infected cultured, and patients’ T-cells

Annika Schnell, Institute Of Clinical And Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany


PO050 – The endogenous HBZ interactome in ATL leukemic cells reveals an unprecedented complexity of host interacting partners involved in RNA splicing

Mariam Shallak, University Of Insubria, Italy


PO051 – Characterizing the transfer of the mobile HTLV-1 accessory protein p8

Florian Simon, Universitätsklinikum Erlangen, Germany


PO052 – Gene targeted editing to disable the oncogenic retrovirus HTLV-1

Susan Smith, The Ohio State University, United States


PO053 – Determining How Stem-loop Structure Thermodynamic Stability Influences Frameshift Efficiency at the HTLV-1 gag-pro Frameshift Site

Mary Soliman, Loyola Marymount University, United States


PO054 – In vivo loss of PD-1 accelerates neoplastic and inflammatory diseases induced by HTLV-1 bZIP factor

Miyu Sonoda, Departments Of Hematology, Rheumatology, And Infectious Diseases, Kumamoto University Hospital, Japan


PO056 – Precise excision of htlv-1 provirus with designer-recombinases

Andrea K. Thoma-Kress, Universitätsklinikum Erlangen, Virologisches Institut, Germany


PO057 – Immunomodulatory drugs (IMiDs) and CelMod-mediated growth suppression of Adult T-Cell Lymphoma/Leukemia (ATL) cells: Functional linkage between Cereblon targets and their down-stream effectors.

Yu Wang, Department of Microbiology, Oita University Faculty of Medicine, Japan


PO058 – In-depth proteomic analysis of human T-cell leukemia virus type 1 particles reveals novel insights into virus-host cell interactions

Nora Willkomm, University Of Minnesota, United States


PO059 – HTLV-1 expression reduces local chromatin looping

Hiroko Yaguchi, Imperial College London, United Kingdom


PO060 – Evaluation of the risk of HTLV-1-associated diseases by analyzing the host immune responses and proviral load

Asami Yamada, Kumamoto University, Japan

PO065 – Neuropathic Pain Profiling in Retroviral Infection (NIPPR):Preliminary results of an observational study of people with HTLV-1 infection

Adine Adonis, Imperial College Healthcare NHS Trust, United Kingdom


PO066 – Daily low-dose prednisone in patients with HTLV-1-associated myelopathy: prospective cohort study in a referral center in Brazil

Tatiane Assone, Fmusp, Brazil


PO067 – By ignoring HTLV-1, is our understanding of the global burden of scabies only skin deep?

Beatrice Cockbain, Imperial College, United Kingdom


PO069 – Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis: A Phase I/II Clinical Trial

Anita Fletcher, National Institute Of Neurological Disease And Stroke/national Institues Of Health, United States


PO070 – Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy: A nationwide registry study in Japan

Naoki Iijima, Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan


PO071 – il-10 and ifn-γ genes polymorphism in htlv-1 infected individuals and their possible relationship with ham/tsp development

Ana Carolina Marinho Monteiro Lima, Universidade Católica Do Salvador, Brazil


PO072 – Drugs efficacy on htlv-1-associated myelopathy/tropical spastic paraparesis treatment: a systematic review

Ana Carolina Marinho Monteiro Lima, Universidade Católica Do Salvador, Brazil


PO073 – The imaging spectrum of HTLV-1 related neurological disease”

Cillian McNamara, Imperial College NHS Healthcare Trust, United Kingdom


PO074 – Immunopathogenic CSF TCR repertoire signatures in HAM/TSP

Satoshi Nozuma, Kagoshima University, Japan


PO075 – Case series: Pediatric T-cell Human Lymphotropic Virus type 1 and its clinical expression

Juan Rojas, Valle University, Colombia


PO076 – HTLV Elite Controllers: A diagnostic challenge and a learning opportunity

Carolina Rosadas, Imperial College London, United Kingdom


PO077 – Expanded Spectrum of Clinical Manifestations associated to HTLV-1 infection

Vicente Soriano, Universidad Internacional de La Rioja, Spain

PO091- fake news in covid era and its impact beyond sars-cov-2: htlv-1 case

Carolina Rosadas, Imperial College London, United Kingdom

Copyright 2021 by ASHM Conference & Events Division | info@htlvconference2022.com | +61 2 8204 0770